Strata Critical Medical Reports Strong Q4, Raises 2026 Revenue & EBITDA Guidance
SRTA has more than doubled off its 52-week low of $2.35.
Summary
Strata Critical Medical announced robust fourth-quarter 2025 financial results, including significant revenue and Adjusted EBITDA growth, and raised its full-year 2026 guidance.
Key Events · Earnings and Guidance · SRTA
-
Strong Q4 2025 Performance
Total revenue increased 83.5% year-over-year to $66.8 million, with Logistics revenue growing 35.3%. Adjusted EBITDA surged 547% to $7.0 million.
-
Full-Year 2025 Exceeds Guidance
Full-year 2025 Adjusted EBITDA of $14.1 million surpassed the high end of the company's guidance range.
-
Raised 2026 Financial Outlook
The company increased its full-year 2026 revenue guidance to $260-$275 million and Adjusted EBITDA guidance to $29-$33 million.
-
Enhanced Liquidity and Strategic Growth
Strata closed a new $30 million asset-backed credit facility and continues to expand its organ recovery platform and aircraft fleet, supporting future growth initiatives.
Analysis · SRTA · Industrial Applications And Services
Strata Critical Medical demonstrated strong operational momentum with an 83.5% year-over-year increase in Q4 revenue and a 547% surge in Adjusted EBITDA, exceeding prior guidance. The raised 2026 revenue and Adjusted EBITDA outlook, coupled with the successful integration of the Keystone acquisition and a new $30 million credit facility, signals continued growth and improved financial health. Investors should view this as a strong indicator of the company's execution and future potential in the critical medical logistics sector.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRTA was trading at $4.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $387.8M. The 52-week trading range was $2.35 to $6.02. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.